Star Therapeutics is a clinical stage biotechnology company discovering and developing best-in-class antibodies to create life-changing therapies for patients, initially addressing unmet needs in hematology and immunology. The company applies its expertise in antibody innovation to interrogate areas of biology that have been overlooked and have the potential to address multiple diseases with a single therapy. Star's leadership team has deep expertise in novel antibody drug development, having invented four first-in-class antibodies including the first approved drug (ENJAYMO®) for cold agglutinin disease, a hematology disease, and other therapies that have demonstrated clinical proof of concept.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/02/25 | $125,000,000 | Series D |
Agent Capital Blue Owl Catalio Capital Cormorant Asset Management Frazier Life Sciences GordonMD Global Investments Janus Henderson Investors New Leaf Venture Partners NYBC Ventures OrbiMed Advisors Qatar Investment Authority RA Capital Management Redmile Group Sanofi Ventures  Sofinnova Investments Soleus Capital Viking Global Investors | undisclosed |
